ESMO Congress 2022: Highlights from the world's premier congress in medical oncology

ESMO Congress 2022, the world's premier congress in medical oncology is happening this year in Paris, France from 9th - 13th September 2022. The congress will attract an international community of experts, across disciplines and all focused on finding the most effective cancer treatment solutions available today. 

Join the ESMO Congress 2022 Group to share conference highlights and to discuss real clinical cases throughout and after the congress.

MedShr’s award-winning technology makes it quick and easy to post a clinical case from the MedShr app while also protecting your patient. Post the most challenging oncology cases from your clinical practice and join the discussion! Post on MedShr 

The author of the most engaging cases will receive a 12 month subscription to MedShr DocSearch, our real-time, AI-assisted medical publication analysis platform, a real game-changer for medical research and improving patient care!  Click here for full details of how to submit your case

ESMO Highlights

This year’s ESMO Congress is the place to build strong, meaningful academic relationships with colleagues and peers in the field of oncology. It’s a chance to learn from experts, network with colleagues, and come together to solve some of the greatest challenges in medical and clinical oncology. It promises a focussed, rich environment for sharing of clinical cases and debates on the latest oncology research, all aimed at providing better care for patients. Ground-breaking new data in oncology will be presented LIVE. 

Here’s a quick guide on what to expect at the event:

1. In the Spotlight:

This year’s ESMO Congress will feature: 

  • Updates in the standard of care of metastatic breast cancer, including special educational sessions on ER+, HER2+ and Triple negative advanced breast cancer.

  • The use of molecular data and precision oncology to directly influence clinical practice

  • The current and future of immunotherapy for Metastatic Non-Small Cell Lung Cancer, a cancer with a historically poor prognosis

  • Educational sessions on adjuvant and perioperative therapy for non-colorectal GI cancers

  • Best practices for non-clear cell renal cell carcinoma


2. ESMO Clinical Practice Guidelines Sessions:

  • Early breast cancer

  • Metastatic non-small-cell lung cancer

  • Cancer of Unknown Primary site (CUP)

  • Biliary tract cancer

  • Primary CNS lymphoma

  • Bladder Cancer 

3. Special Sessions on:

  • The impact of COVID-19 on cancer services globally: Challenges and lessons learned

  • Hard-to-treat cancers such as aggressive small cell lung cancers and glioblastomas

  • The Universal Health Coverage (UHC) dilemma: Can we afford to pay for what we want?

  • Insights into the new CNS WHO classification: Novel concepts and therapeutic implications for gliomas

    4. The future of digital health and technology in oncology:

  • What is the future of digital medicine for cancer patients? (Keynote lecture)

  • The road towards clinical implementation of artificial intelligence (AI) in oncology

  • Complex technologies for diagnosis: How do we implement and use them globally?

  • State-of-the-art: Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours


Join the ESMO Congress 2022 Group to see the latest data and insights from the Congress as they are released.

Loading Author...

Comments

Sign in or Register to comment

LoadingLoading